Issue: January 2019
November 30, 2018
1 min read
Save

First-in-Human Trial Evaluates UC Therapy

Issue: January 2019
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

PEER-TESTED TOP 5

OSE Immunotherapeutics has received authorization to initiate a phase 1 clinical trial of OSE-127, a monoclonal antibody targeting the IL-7 receptor with a novel mechanism of action, for the treatment of ulcerative colitis, according to a company press release.

“Initiating this phase 1 study represents a leap forward for OSE-127,” Alexis Peyroles, CEO of OSE Immunotherapeutics, said in the release. “On the heels of publishing the unique mechanism of action of OSE-127 in Nature Communications, we believe even more strongly that this asset has significant potential therapeutic value for treatment of autoimmune diseases and chronic inflammation.”

The first-in-human dose-escalation study will aim to evaluate the safety and tolerability of single- and multiple-ascending intravenous and subcutaneous doses of OSE-127, according to the release.

The randomized, double-blind, placebo-controlled phase 1 trial is expected to comprise 63 healthy volunteers.